Ann: Investor Presentation, page-7

First 7 Last

Share
Profile

Follow
Eqz

3,926 Posts.

1268

21/06/21

13:40

Post #: 53966501
Share

Originally posted by candidcamera: ↑

Unfortunately, my unpopular view that I've expressed before still stands. This company doesn't have the revenue to warrant a higher share price and frankly, with around $1 million in revenue per year, and 120 million shares on offer, I'm surprised it's as high as it is.

What makes it really disappointing and bewildering for me is that the company has so much going for it:
– Unique and life-changing products that deliver great patient outcomes.
– A company that's been around for over 20 years, selling its products for over 15, 40,000+ successful operations (so lots of stats to back it up).
– Sound management.
– Good and relevant partnerships.
– Increasing diversity with a pipeline of new products and whole areas into which it can grow.
– Relevant permissions in place to sell into the biggest markets in the world (China, USA and Europe).
– Distribution deals to take advantage of those permissions.
– Very positive media and medical commentary.
– A tiny foothold in a multi-billion dollar industry (hence a very long runway for growth)

On paper, you have to think (scream!): What's not to like?

I don't think it's a failing of the management or the sales teams. It's just that hospitals aren't buying it in anywhere near the number required for a share price movement. They're not buying it because the doctors aren't recommending it (stuck on their traditional, tried-and-true products?). Sure, the Q-on-Q percentage increases look good. But when you're starting from such a very low base, that's not so impressive. It's the revenue that counts and until that goes up – substantially, like around 10x what it is now – I can't see how the share price will go up.

I'm only holding because I don't want to realise the loss, so might as well hang on and hope. Now, I'm hoping that a big medtech buys OSX, because I think it's unrealistic to expect the kind of organic growth that would be needed to get the share price over $1.

Expand

Can you give me an examples of micro cap Biotech where revenues justify its market cap?

$50M is well priced in comparison to the industry and its peers.

I'm starting to lose my patience a tad, admittedly it is holding up pretty well given the tax month. If it was not for the cash position I would be out.

OSX Price at posting: 43.0¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Close: Index treads water as Energy stocks lead

PNR

Pantoro Gold Confirms High-Grade Extensions

SCP

Scalare Partner's up 44% on todays news

ASX Market Open: All eyes on Aussie CPI data; ASX tipped to trade flat

WC8

Wildcat’s PFS elicits lacklustre response

First 7 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.2¢		Change -0.001(4.17%)		Mkt cap ! $2.278M

Open	High	Low	Value	Volume
1.2¢	1.2¢	1.1¢	$30.78K	2.598M

Buyers (Bids)

No.	Vol.	Price($)
17	2761880	1.1¢

Sellers (Offers)

Price($)	Vol.	No.
1.2¢	759938	4

View Market Depth

No.	Vol.	Price($)
17	2761880	0.011
25	7956890	0.010
11	2533654	0.009
6	2100000	0.008
4	567857	0.007

Price($)	Vol.	No.
0.012	916874	7
0.013	1158332	3
0.014	2120000	5
0.015	2516993	13
0.016	2554251	5

Last trade - 11.01am 30/07/2025 (20 minute delay)

OSX (ASX) Chart

Ann: Investor Presentation, page-7

ASX Market Close: Index treads water as Energy stocks lead

Pantoro Gold Confirms High-Grade Extensions

Scalare Partner's up 44% on todays news

ASX Market Open: All eyes on Aussie CPI data; ASX tipped to trade flat

Wildcat’s PFS elicits lacklustre response

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Presentation, page-7

Top Stories

ASX Market Close: Index treads water as Energy stocks lead

Pantoro Gold Confirms High-Grade Extensions

Scalare Partner's up 44% on todays news

ASX Market Open: All eyes on Aussie CPI data; ASX tipped to trade flat

Wildcat’s PFS elicits lacklustre response

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News